Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
Phase III study will evaluate effects of otelixizumab, an investigational
anti-CD3 monoclonal antibody, on preservation of endogenous insulin secretion
CAMBRIDGE, Mass., April 9, 2008 /PRNewswire/ -- Tolerx, Inc., a
biopharmaceutical company engaged in the discovery and development of novel
therapies for immune-mediated diseases, today announced that it is proceeding
toward the initiation of a Phase III study of otelixizumab in new-onset type 1
diabetes. Tolerx is initiating this pivotal trial after reviewing the
results of the otelixizumab development program with the US Food and Drug
Administration (FDA) at an End of Phase II meeting.
Posts
No comments :
Post a Comment